Searched for
RESPIRATORY DISEASES BUSINESS
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Kerala reports fresh Nipah Virus case: Check symptoms, ways to prevent and other key detailsKerala is on high alert after a man in Kozhikode district tested positive for Nipah virus. Health officials are tracing contacts and implem...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- How South African scientists identified hantavirus on a cruise ship thousands of miles awayA cruise ship outbreak was identified as hantavirus. South African experts rapidly investigated a passenger evacuated with pneumonia. Initi...
- Wealth creation is also about ignoring noise on the street: 15 mid- and small-cap stocks from different sectors which fit the billIn the April 2022-September 2024 bull market, every management appeared capable. Margins expanded, working capital looked manageable, capit...
- From care to commerce: How phydigital healthcare is turning patient programmes into big businessIndia's healthcare is changing. Value is moving from hospitals to patients' daily lives. A new 'phydigital' model combines physical and dig...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 33%To get clarity on the markets, there are three questions to which you need answers. First: When will the war end? Second: How long will it ...
- Mankind Pharma’s Rx for success: Aatmanirbhar push, affordable careMankind Pharma, guided by Ramesh and Rajeev Juneja, is a leading Indian pharmaceutical firm. The company focuses on mass-market drugs and h...
- Mankind Pharma to acquire Combihale and Daffy brands from Dr Reddy's LaboratoriesMankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent. The acquisition of the product is expected t...
- Dr Reddy's Laboratories to buy UCB's Indian arm for Rs 800 croreUCB, listed on Euronext Brussels, has operations in nearly 40 countries with revenues of €3.3 billion (about Rs 22,275 crore) in 2014.
- Dr Reddy’s agrees to buy UCB business in India for Rs 800 croreThe deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement ...
- Vishal Bali's Medwell ties up with Philips for Med Gear supplyBali said the home care division of Philips will also train therapists, who can visit patients' homes and operate the equipment.
- Aurobindo Pharma gets USFDA nod for generic drugsAurobindo Pharma Ltd has received two more approvals from USFDA taking up the count generic approvals for the company to 35.
Load More
